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Colorectal cancer (CRC) is the third leading cause of cancer-related death in the 
United States. Chemopreventive therapies could be effective way to treat CRC. 
Tolfenamic acid, one of the NSAIDs, shows anti-cancer activities in several types of 
cancer.  Aberrant Wnt/β-catenin regulation pathway is a major mechanism of colon 
tumorigenesis. Here, we sought to better define the mechanism by which tolfenamic 
acid suppresses colorectal tumorigenesis focusing on regulation of β-catenin pathway. 
Treatment of tolfenamic acid led to a down-regulation of β-catenin expression in dose 
dependent manner in human colon cancer cell lines without changing mRNA. MG132 
inhibited tolfenamic acid-induced downregulation of β-catenin and exogenously 
overexpression β-catenin was stabilized in the presence of tolfenamic acid.  
Tolfenamic acid induced an ubiquitin-mediated proteasomal degradation of β-catenin. 
In addition, tolfenamic acid treatment decreased transcriptional activity of β-catenin 
and expression of Smad2 and Smad3 while overexpression of Smad 2 inhibited 
tolfenamic acid-stimulated transcriptional activity of β-catenin. Moreover, tolfenamic 
acid decreased β-catenin target gene such as vascular endothelial growth factor 
(VEGF) and cyclin D1. In summary, tolfenamic acid is a promising therapeutic drug 





























Thesis submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 













Dr. Seong-Ho Lee, Chair 
Dr. Byung-Eun Kim 












































I would like to take this opportunity to acknowledge some of the people. Without 
them, completion of Master degree itself would not be possible. I want to express my 
deepest thanks to Dr. Seong-ho Lee, my advisor, who gives me opportunity to 
pursuing my goal of starting graduate program and helps me open my view of cancer 
area in biomedical science field.  He is always very supportive and guides me to the 
correct direction. And also, I want to express my deepest thanks to Dr. Lee for taking 
time and effects to revising my thesis.  
I would also like to thank Dr. Taekyu Ha, our pervious post-doc, who spent a lot 
of time to guide me and answer my questions with patience. Thanks to our other left 
post-docs: Dr. Xuyu Yang, Dr. Kuijin Kim, and Dr. Jinboo Jeong, for their guidance 
on my research.  
My sincere thanks also go to the members of my defense committees: Dr. Seong-
ho Lee, Dr. Byung-Eun Kim, and Dr. Shaik Ohidar Rahaman, who spent their 
precious time to elaboration of this thesis defense. 
I am grateful to all the helps from members of Dr. Lee’s lab: Jihye Lee, Charlene 
Jiang, Elizabeth Leahy and Ruth Clark. Many thanks go to my friends in US and in 
China. 
Finally, I would like to acknowledge my parents, Jidong Lou and Shuping 
Zeng. Without their encouragement, support and love, I would not complete this 




Table of Contents 
 
Acknowledgements ..................................................................................................... ii 
Table of Contents ....................................................................................................... iii 
List of Figures ............................................................................................................. iv 
Chapter 1: Background .............................................................................................. 1 
1.1 Significance of chemoprevention and chemotherapy in colorectal cancer 
(CRC) ....................................................................................................................... 1 
1.2 CRC and nonsteroidal anti-inflammatory drugs (NSAIDs).......................... 2 
1.2.1. Aspirins ....................................................................................................... 3 
1.2.2. Sulindac sulfide (SS)................................................................................... 3 
1.2.3. Celecoxib .................................................................................................... 4 
1.3 Tolfenamic acid ............................................................................................ 5 
1.4 Introduction of colon cancer tumorigenesis .................................................. 6 
1.4.1. Significant of β -catenin in CRC ................................................................. 6 
1.4.2. Upstream regulators of β –catenin: Wnt, TGF-β, PI3K .............................. 8 
Chapter 2: Materials and Methods ......................................................................... 11 
2.1 Materials ..................................................................................................... 11 
2.2 Cell culture .................................................................................................. 11 
2.3 Isolation of RNA and semi-quantitative RTPCR........................................ 11 
2.4 DAPI staining.............................................................................................. 12 
2.5 Transient transfection and Luciferase assay ............................................... 12 
2.6 SDS-PAGE and Western blot: .................................................................... 13 
2.7 RNA interference ......................................... Error! Bookmark not defined. 
2.8 Statistical analysis ....................................................................................... 13 
Chapter 3: Tolfenamic acid downregulates β-catenin at post-transcriptional level 
in human colon cancer cells ..................................................................................... 14 
3.1 Effects of NSAIDs and dietary phytochemicals on cell growth arrest in 
SW480 cell .............................................................................................................. 14 
3.2 Tolfenamic acid decreased β-catenin expression level in human colon 
cancer cells .............................................................................................................. 16 
3.3 Tolfenamic acid induced ubiquitination and degradation of β-catenin ...... 20 
3.4 Tolfenamic acid-induced crosstalk between TGF-β/Smad and Wnt/β-
catenin signaling ..................................................................................................... 23 
3.5 Tolfenamic acid suppressed Smad2-stimulated transcriptional activity of β-
catenin ..................................................................................................................... 25 
3.6 Tolfenamic acid reduced expression of β-catenin target genes. ................. 27 
Chapter 4: Discussion, Conclusion and Future Perspective ................................. 28 
4.1 Discussion ................................................................................................... 28 
4.2 Conclusion and Future Perspective ............................................................. 31 













List of Figures 
Figure 3.1. Several NSAIDs and dietary compounds decrease β-catenin expression 
level.   
Figure 3.2. Tolfenamic acid decreased β-catenin protein expression level. 
Figure 3.3. Tolfenamic acid induced ubiquitination and degradation of β-catenin. 
Figure 3.4. TGF-β/Smad signaling involved in tolfenamic acid treatment. 
Figure 3.5. Tolfenamic acid suppressed Smad2-stimulated transcriptional activity of 
β-catenin 




Chapter 1: Background  
1.1 Significance of chemoprevention and chemotherapy in colorectal cancer (CRC)  
Cancer is one of the major causes of death throughout the world and second 
leading cause of death in US. Based on the annual report that American Cancer 
Society estimated, 1,685,210 new cancer cases will be diagnosed and 595,690 cancer 
deaths will occur in the United States in 2016 (1). Among them, colorectal cancer 
(CRC) occupy third places in prevalence and cancer-related death in both men and 
women (1). Around 75% incidences of colorectal cancer are sporadic and remaining 
25% is hereditary. Numerous epidemiological studies showed that CRC can be 
preventable by changing eating pattern and lifestyle and avoiding environmental risk 
factors. They include smoking, drinking, obesity, physical inactivity, low calcium 
intake, low intake of fruit and vegetable and high intake of red or processed meet (2). 
For the past decades, there was a decent decreasing cancer mortality in the United 
States due to the advances in early detection and screening technology (3). However, 
projected numbers of CRC-related deaths in US is 49,190 in 2016 (1) because 
advanced stage of CRC remain untreatable. Therefore, it is urgent to screen and find 
effective anticancer compounds for chemoprevention. Chemopreventive strategy 
using nature products or synthetic drugs could prevent or delays the onset and reverse 
the process of several types of cancers (4). More specifically, long term use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) has been showed to prevent CRC in 





1.2 CRC and nonsteroidal anti-inflammatory drugs (NSAIDs)  
NSAIDs are a class of drugs that contain analgesic, antipyretic, and anti-
inflammatory properties. Most well-known mechanism of NSAIDs is to inhibit 
prostaglandin (PG) synthesis via deactivating activity of cyclooxygenase-1 (COX-1) 
and cyclooxygenase-2 (COX-2), first liming enzymes of prostaglandin biosynthesis 
(8). COX enzyme converts arachidonic acid to prostaglandin H2 (PGH2). Then 
PGH2 is converted into diverse PG including PGE2, PGI2, PGJ2 and thromboxane 
and carries out a diverse biological activity including oncogenesis and 
thrombogenesis. Another function is a cytoprotective activity in the gastric mucosa 
and renal epithelial cells (9). Thus, long-term use of COX inhibitors may cause 
gastrointestinal tract bleeding, ulcer or kidney failure, which mainly due to inhibition 
of COX-1 (10). While COX-1 is constitutive function, COX-2 is an inducible enzyme 
and responsible for the chemopreventive effect of NSAIDs. As COX-2 expression 
and PG synthesis is elevated in CRC (11), COX-2 inhibitors such as celecoxib are 
regarded as the promising CRC preventive agents. The responsible anticancer 
mechanisms of NSAIDs include increased apoptosis, cell-cycle arrest and inhibition 
of angiogenesis (12, 13). However, unexpected side effect and toxicity led to 
withdrawal of COX-2 selective inhibitors from market. However, inhibition of COX 
is not the only pathway of chemopreventive activities of NSAIDs, but COX-
independent pathways exist (14, 15). Thus, many research group study to find 





Aspirin has been the most commonly used to treat inflammation, fever, and pain 
in clinical setting since Felix Hoffmann at Bayer in Germany found that extracts from 
willow bark possessed anti-inflammatory and anti-pyretic activity in 1898 (16). It is 
typical traditional NSAID inhibiting both COX-1 and COX-2 irreversibly by 
acetylation of serine residues in the active and catalytic binding domain for 
arachidonic acid (11, 13). Low-dose of aspirin intake (around 70–100 mg/day) is 
widely used for health benefit including prevention of cardiovascular disease and 
CRC. Kune et al. reported an inverse association between use of aspirin and the risk 
of CRC through human clinical trials for the first time (17). In addition, recent other 
cohort and case-control studies indicated that aspirin may be effective at preventing 
several types of cancer particularly in colorectal cancer (18-20). As a COX inhibitor, 
aspirin inhibits synthesis of prostaglandin E2 (PGE2) which is well known oncogenic 
pathway in tumor development and progression. However, aspirin effect is also 
observed in COX-null colorectal cancer cells, proposing COX-independent anticancer 
pathway (21). Pathi et al pointed that aspirin inhibits specificity protein (Sp), Sp1, 
Sp3 and Sp4 transcription factors through caspase-dependent proteolysis in colon 
cancer cells (22). 
 
1.2.2. Sulindac sulfide (SS)  
Sulindac has been shown to inhibit tumorigenesis activities including 
angiogenesis and tumor cell invasion in preclinical setting (23, 24). For example, 




sulfide is a metabolite of sulindac and effectively suppresses colon cancer as an 
inhibitor of COX-1 and COX-2 whereas it results in severe side effect including 
gastrointestinal ulceration and bleeding (30). Sulindac, lacks COX inhibitory 
activities, can undergo reversible reduction to pharmacologically active sulindac 
sulfide. And sulindac and sulindac sulfide will also irreversibly oxidize to sulindac 
sulfone metabolites with hepatotoxicity (26).  
Sulindac sulfone has been shown that anti-tumorigenesis undergoes COX 
independent pathway in animal model in different cancer models (27-30). Some 
mechanistic studies showed that sulindac sulfone can suppress oncogenic β-catenin 
signaling by inhibiting cyclic guanosine monophosphate phosphodiesterase (cGMP 
PDE) (31). Sulindac sulfide also induces the expression of tumor suppressor NSAIDs 
activated gene 1 (NAG-1) (32). However, sulindac do not completely protect all 
individuals from developing cancer. Keller et al pointed out that treatment of sulindac 
may produce resistant adenomas and breakthrough carcinomas, which limit 
chemopreventive activity of NSAIDs (33).  
 
1.2.3. Celecoxib 
Celecoxib is most common selective COX-2 inhibitor. Many side effects 
including gastrointestinal ulceration and kidney failure are mainly attributed to 
inhibition of COX-1. As the result, selective COX-2 inhibitor can avoid side effects 
of non-selective NSAIDs because they are not targeting COX-1 (10). Prolonged 




side effects, such as an increase in blood pressure, myocardial infarction, and stroke 
(10, 34, 35).  
Celecoxib can directly inhibit the DNA-binding activity of Sp1 transcription 
factor which is a crucial driver of VEGF overexpression in cancer cells (36). In 
addition, celecoxib has been shown to inhibit invasion through downregulation of 
matrix metallopreoteins (MMP) 2 and 9, the enzymes to help disassociate with cell 
junctions and eventually lead to metastasis (37, 38). All of these evidences suggest 
NSAIDs can go through COX-independent pathway to exhibits anti-cancer effects. 
 
1.3 Tolfenamic acid  
Tolfenamic acid ((N-(2-methyl-3-chlorophenyl)-anthranilic acid) is a derivative 
of anthranilic acid (39) and inhibits inflammation through inhibition of leukotriene 
B4 (LTB4)-induced chemotaxis (40) and has been broadly used for the treatment of 
migraines. The optimal dose of migraine treatment is 200 mg when the first 
symptoms appear (41). Recently we reported an anti-inflammatory activity of 
tolfenamic acid in human CRC (42). 
Like other NSAIDs, tolfenamic acid exhibits anti-cancer activities in different 
cancer models, such as lung, esophageal, breast, prostate, ovary and pancreatic cancer 
cells (43-49). Since tolfenamic acid show little side effect (41, 50), our lab chose 
tolfenamic acid as a study compound and investigated detailed anti-cancer 
mechanisms.   
We observed that tolfenamic acid induced growth arrest and apoptosis in colon 




generation (52), ESE-1/EGR-1 activation (53) and  mitogen-activated protein kinases 
(MAPK) pathway (54).  Recently, we also found tolfenamic acid suppressed 
formation of tumor in Apc
Min+/
 mice in vivo (55). In terms of metastasis, Abdelrahim 
et al have been showed tolfenamic acid was associated with suppression of vascular 
endothelial growth factor (VEGF) and its receptor (VEGFR1) in pancreatic cancer 
(56, 57). Taken together, there are several proposed molecular mechanisms of anti-
tumorigenic activity by tolfenamic acid.  
 
 
1.4 Introduction of colon cancer tumorigenesis 
1.4.1. Significant of β -catenin in CRC 
Truncated deletion of APC gene is identified in familial adenomatous polyposis 
(FAP) syndrome, which is characterized by early onset colorectal cancer (58) and 
ovarian tumors (59). Wild-type APC make a complex with axin, GSK3b, casein 
kinase 1 and β-catenin and facilitates the proteasomal degradation of β-catenin 
through ubiquitination. As a result, mutation in APC gene leads to accumulation of β-
catenin (60). In addition, mutation of axin, the scaffolding protein in complex 
formation, or deletion of β-catenin at N-terminal Ser/Thr destruction motif also 
escapes β-catenin degradation. Surplus β-catenin is translocated into nuclear and 
binds to TCF4. The β-catenin/TCF4 complex directly binds to TCF-binding site and 
regulates expression of target genes such as VEGF, cyclin D1 and c-myc. Thus, β-
catenin is promising preventive and therapeutic target for colorectal cancer (61, 62).  
β-catenin is a downstream target of Wnt pathway (63). It was first classified as a 




the architecture of epithelia. With down-regulation of E-cadherin, β-catenin can be 
released from cadherin complexes. The level of β-catenin in cells is tightly controlled 
through interactions with other proteins, such as APC, GSK-3β, and axin (64, 65). 
With the absence of Wnt, cytoplasmic β-catenin forms a complex with APC, 
glycogen synthase kinase 3 (GSK3), axin and casein kinase 1 (CK1). β-catenin gets 
phosphorylated and recognized by ubiquitin ligase, and lead to proteasomal 
degradation at 26S proteasome (68) through interaction with β-TrCP (66). However, 
with the presence of Wnt ligand, Axin-mediated phosphorylation and degradation of 
β-catenin was disrupted by receptor complex formed between Frizzled (Fz) and low 
density lipoprotein receptor-related protein 5/6 (LRP5/6). Most identified mutations 
results in removing binding sites of beta-catenin and axin, and results in β-catenin 
elevated. Therefore, β-catenin accumulated and moved into nucleus to function as a 
coactivator for TCF to activate Wnt-response downstream gene by interacting with N 
terminus of DNA-binding proteins lymphoid enhancer-binding factor 1/T cell-
specific transcription factor (LEF/TCF) proteins family (60, 67).  
Nuclear β-catenin accumulation can be detected in more than 80% of CRC tumors 
(68).  Moreover, an epidemiological study conducted by Baldus et al pointed that 
high levels of nuclear β-catenin have been associated with a poor prognosis in CRC 
patients (69) and this idea was also supported by other groups (70-72). Oncogenic 
target genes such as VEGF and cyclin D1 can also be transactivated by β-catenin 
translocation and binding to LEF/TCF (63, 73-75). Thus β-catenin downregulation 
and the β-catenin/TCF complex interruption could be promising strategies for 




1.4.2. Upstream regulators of β –catenin: Wnt, TGF-β, PI3K 
Wnt. The Wnt signaling plays important roles in regulation of tumorigenesis. 
Dysregulation of Wnt signaling is involved in the development of multiple cancers, 
especially in colorectal cancer (76). There are two different pathways of Wnt 
signaling, one is canonical Wnt pathway for cell growth and apoptosis, and another is 
non-canonical Wnt pathway (the planar cell polarity, PCP pathway; and the WNT–
Ca
2+
 pathway) for control of tissue polarity and cell movement (77). Different 
ligands’ activation can be used to differentiate canonical (Wnt1, 2, 3, 3A, 8A, 8B, 
10A and 10B) and non-canonical (Wnt4, 5A, 5B, 6, 7A, 7B) pathways(78). Numbers 
of studies have been shown that dysregulation of canonical Wnt can lead to cancer 
development and progression (79).  
TGF-β. Transforming growth factor beta (TGF-β) represents a major growth-
inhibitory signal that normal cells, such as epithelial cells, evade in order to become 
cancer cells (80). Smad transcriptional factors serve as major mediators in TGF-beta 
signaling of the Smad-dependent pathway (81). TGF-β ligands bind to type two TGF-
β receptor and then recruit type one TGF- β receptor. These allow Smad2 and Smad3 
phosphorylation. Activated Smad proteins bind with Smad4 and translocate to 
nucleus to mediate gene activities (82, 83). In cancer development, TGF-β may have 
dual functions: a tumor suppressor or tumor promoter, depending on the stage of 
tumorigenesis. TGF-β could inhibit cell growth in normal or pre-neoplastic epithelial 
cells. However, TGF-β would promote tumor growth and metastasis in late stage of 




Recent studies demonstrated TGF-β/Smad and Wnt/β-catenin signaling cross-talk 
to each other (85, 86). TGF-β and Wnt ligands can work together to regulate cell 
differentiation and apoptosis by controlling gene expression. Taketo et al developed 
Smad4/APC heterozygotes mice, and observed more malignant tumors in these mice 
compare to those in APC heterozygotes mice (87). Another in vivo study performed 
by Hamamoto et al, Smad2/APC heterozygotes mice was observed that disruption of 
Smad2 mediated malignant progression of intestinal tumors in the APC mice, but the 
difference was not severe (88). More work need to be done in order to understand 
TGF-β and Wnt interactions.  
PI3K. Phosphoinositide 3-kinase (PI3K) is a family of enzymes that important for 
cell cycle, proliferation, survival and protein synthesis (89). Dysregulation of 
oncogenic PI3K pathway would drive to cancers. In cancer cells, receptor tyrosine 
kinase (RTK) constitutively activated and leads to PI3K activation (90). Since PI3K 
is a critical mediator in cancer development, making it an important target in the 
treatment of cancer. Recent study also indicated that PI3K would have some 
association between β-catenin. Liu et al suggested level of β-catenin could alter PI3K 
effect on NF-kappa B activity in CRC cells (91). The detailed β-catenin and PI3K 
pathway interactive still remain unclear.  
 
 
In the present study, we examined whether treatment of tolfenamic acid could 
alter β-catenin expression and found β-catenin decreased in dose dependent manner in 
human colon cancer cell lines. We further found β-catenin downregulation by 




We also found there is a cross-talk between Wnt and TGF- β signaling in our 
designed study. Tolfenamic acid treatment would downregulate Smad2 and Smad3 
via overexpression of Smad 2, but not Smad3. Moreover, tolfenamic acid also 
decreased β-catenin target gene. Thus, tolfenamic acid could be a potential cancer 





Chapter 2: Materials and Methods 
2.1  Materials 
Tolfenamic acid was purchased from Cayman Chemicals (#70480) (Ann Arbor, 
Michigan, and dissolved in dimethyl sulfoxide (DMSO). MG-132 was purchased 
from Calbiochem (San Diego, CA). Antibodies for β-catenin (#9562), Smad2 (#5339) 
and Smad3 (#9513) were purchased from Cell Signaling (Beverly, MA). Antibodies 
for cyclin D1 (sc-718), green fluorescent protein (GFP) (sc-8334), and actin (sc-1615) 
were purchased from Santa Cruz (Santa Cruz, CA). The GFP-tagged β-catenin 
expression vector was described previously (92, 93). Media for cell culture were 
purchased from Invitrogen (Carlsbad, CA). All chemicals were purchased from Fisher 
Scientific or VWR, unless otherwise specified. 
 
2.2 Cell culture 
Human colon adenocarcinoma cells (SW480, HCT116, LoVo and CaCO2) were 
purchased from American Type Culture Collection (Manassas, VA) and grown in 
Dulbecco’s modified Eagle medium (DMEM/F-12) media supplemented with 10% 
fetal bovine serum (FBS), a mixture of penicillin (100 U/mL) and streptomycin 
(100µg/mL) under a humidified atmosphere of 5% CO2 at 37°C.  
 
2.3 Isolation of RNA and semi-quantitative RTPCR  
Total RNA was prepared using RNeasy Mini kit (Qiagen). Total RNA (1 μg) was 




manufacturer’s instruction. PCR was carried out using ReadyMix Taq polymerase 
(Sigma) with primers for human β-catenin and GAPDH.   





Reverse 5’-TGGCAGGTTTTTCTAGACGG-3’.   
 
2.4 DAPI staining  
The cells were washed with PBS three times and fixed with 3.7% formaldehyde.  
After three times washed with PBS, 0.2% Triton X-100 was used to permeabilize the 
cells for 5 mins. The cells washed again, and 4', 6-diamidino-2-phenylindole (DAPI 
stock diluted 1:5000 in PBS) labeling solution was added at room temperature for 5 
mins. The Nuclear DNA images were taken by fluorescence microscope.  
 
2.5 Transient transfection and Luciferase assay  
The expression vectors (for GFP-tagged β-catenin, Smad2 and Smad3) and luciferase 
reporters (TOP/FOP FLASH) were transiently transfected using PolyJet DNA 
transfection reagent (SignaGen Laboratories, Ijamsville, MD, USA) according to the 
manufacturer’s instruction. For luciferase assay, the cells were transfected with 
plasmid containing β-catenin/TCF-LEF-responsive (TOP-FLASH) and mutant (FOP-




for 24h. The cells were harvested in 1× luciferase lysis buffer. The luciferase activity 
was measured and normalized to the pRL-null luciferase activity using a dual-
luciferase assay kit (Promega).  
 
2.6 SDS-PAGE and Western blot:   
Cells were washed with 1 × phosphate-buffered saline (PBS), sat on ice for 15 
minutes in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio Products, 
Ashland, MA) supplemented with protease inhibitor cocktail (Sigma Aldrich, St. 
Louis, MO) and phosphatase inhibitor cocktail (Sigma Aldrich) and then harvested. 
The cell lysate was centrifuged at 12,000 × g for 15 min at 4°C. Protein content was 
measured by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). The 
proteins were separated on SDS-PAGE, transferred to nitrocellulose membranes 
(Osmonics, Minnetonka, MN) and blocked in 5% non-fat dry milk in Tris-buffered 
saline containing 0.05% Tween 20 (TBS-T) for 1h at room temperature. Membranes 
were probed with specific primary antibodies in 3% Bovine Serum Albumin (Santa 
Cruz) at 4 °C overnight and then with horse radish peroxidase (HRP)-conjugated 
immunoglobulin G (IgG) for 1 h at room temperature. Chemiluminescence was 
detected with Pierce ECL Western blotting substrate (Thermo Scientific) and 
visualized by ChemiDoc MP Imaging system (Bio-Rad, Hercules, CA). 
 
2.7 Statistical analysis  
Statistical analysis was performed with ImageJ (NIH) and SPSS. Data was analyzed 





Chapter 3: Tolfenamic acid downregulates β-catenin at post-
transcriptional level in human colon cancer cells 
 
3.1 Effects of NSAIDs and dietary phytochemicals on cell growth arrest in SW480 cell 
According to recent studies, several types of NSAIDs and dietary phytochemicals 
possess strong anticancer activity in CRC (4). Since aberrant regulation of Wnt/β-
catenin is common during colon tumorigenesis (94-96), we investigated if several 
NSAIDs and dietary phytochemicals may affect β-catenin expression in human colon 
cancer cells. Selected NSAIDs (50 µM sulindac sulfide, 50 µM tolfenamic acid, 50 
µM aspirin, 50 µM diclofenac, 50 µM SC-560 and 50 µM celecoxib) and 
phytochemicals (50 µM epigallocatechin-3-gallate, 50 µM resveratrol and 50 µM 
genistein) are broadly used as potential anticancer drugs to treat many types of 
cancer. Sulindac sulfide (a metabolite of sulindac), tolfenamic acid, aspirin and 
diclofenac are non-selective NSAIDs. SC-560 and celecoxib is COX-1 and COX-2 
selective inhibitor, respectively. For screening the compounds, we used SW480 
human colorectal adenocarcinoma cells. This cell line has APC mutation and active 
β-catenin signaling. The results indicated that sulindac sulfide and tolfenamic acid 
significantly decreased expression of β-catenin and celecoxib and epigallocatechin-3-
gallate treatment tend to decreased β-catenin expression (Figure 3.1A). These data 
suggest that decreased β-catenin could be a potential mechanism of anticancer 
activity of sulindac sulfide and tolfenamic acid. We selected tolfenamic acid for 
further studies due to its novelty and potential of promising anticancer drugs and less 















Figure 3.1. Several NSAIDs and dietary compounds decrease β-catenin 
expression level. SW480 cells were treated for 24 hours with 50 μM of different 
compounds (DMSO, 6 NSAIDs and 3 dietary phytochemicals) listed above. Lysates 
were harvested and western blot was performed to analyze the β-catenin expression 




3.2 Tolfenamic acid decreased β-catenin expression level in human colon cancer cells 
We tested if tolfenamic acid downregulates expression of β-catenin in dose 
dependent manner. The cells were treated with different dose of tolfenamic acid (0, 
10, 20 30 or 50 uM) for 24 hours and western blot was performed against β-catenin 
and actin antibody. As shown in Fig. 3.2A, tolfenamic acid decreased β-catenin 
expression in dose-dependent manner in SW480. TOP/FOPflash data also confirmed 
β-catenin declining with the tolfenamic acid treatment (Figure 3.2A, bottom) because 
the downstream target gene luciferase expression decresed . We also tested if 
tolfenamic acid affect expression of β-catenin in other human colorectal cancer cells 
with different genetic background. HCT116 and LoVo cells decreased β-catenin 
expression in response to tolfenamic acid, but Caco-2 cells did not change the β-
catenin expression (Figure 3.2B).  
Since β-catenin downregulation is associated with increase apoptosis, we stained 
tolfenamic acid-treated cells with DAPI to look at DNA fragmentation and chromatin 
condensation. As a result, we found an increase of DNA fragmentation in the SW480 























Figure 3.2. Tolfenamic acid decreased expression of β-catenin protein in dose-
dependent manner in human colorectal cancer cells. A top and B) SW480, 
HCT116, LoVo, and CaCO2 were treated with tolfenamic acid as labeled for 24 
hours. Lysates were harvested and western blot was performed to analyze the β-
catenin expression level. Actin is the housekeeping marker; A bottom) SW480 were 
transfected with reporter plasmids (TOP/FOP, pRL-null). Cells were subsequently 
treated with tolfenamic acid as labeled for 24 hours. Luciferase activity was measured 
using a dual luciferase assay kit (Promega). Data represent mean ± SD from three 
replicates. C) SW480 cells were treated with tolfenamic acid, 0, 10, 20, 30, 50 µM, 
respectively for 24 hours. . The Nuclear DNA was stained with 4', 6-diamidino-2-




3.3 Tolfenamic acid induced ubiquitination and degradation of β-catenin 
 
In order to test if tolfenamic acid decreases β-catenin expression through 
transcriptional downregulation of β-catenin gene, RT-PCR was performed to measure 
mRNA. As a result, the β-catenin mRNA level in SW480 cell was not changed with 
tolfenamic acid treatment (Figure3.3A), indicating that downregulation of β-catenin 
by tolfenamic acid is not related to transcriptional regulation, instead at 
posttranscriptional level in colon cancer cells. Since some literatures showed β-
catenin is directly targeted by ubiquitination and subsequent degradation (64, 97), we 
tested if proteasomal degradation mediates tolfenamic acid-induced β-catenin down-
regulation. The cells were co-treated with MG-132 (inhibitor of proteasome) and 
tolfenamic acid and then western blot was performed. As shown in Figure 3.3B, 
tolfenamic acid-induced β-catenin down-regulation was blocked by the treatment of 
MG-132. Moreover, overexpressed exogenously GFP–tagged β-catenin was 
decreased by tolfenamic acid (Figure 3.3C). These data suggest that tolfenamic acid 
induces β-catenin degradation through activating ubiquitin-proteasome system. We 
also comparied protein stability with the treatment of tolfenamic acid by performing 
cycloheximide (CHX) assay. CHX is an inhibitor of protein biosynthesis due to its 
prevention in translational elongation. Interestingly, tolfenamic acid decreased the 
stability of β–catenin protein in 12 hours but slightly increased the stability at 24 
















Figure 3.3. Tolfenamic acid induced ubiquitination and degradation of β-
catenin. A) SW480 cells were treated with tolfenamic acid using indicated amount 
for 24 hours. Semi-quantitative reverse transcriptase (RT)-PCR was performed for β-catenin 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. B) SW480 cells were 
pretreated with MG-132 for 30 mins and co-treated with tolfenamic acid for 24 hours. 
Whole cell lysates were harvested and western blot was performed to analyze the β-
catenin and actin expression level. C) SW480 cells were transfected with GFP-tagged 
β-catenin expression vector and then treated with tolfenamic acid at different 
concentration. Western blot was performed to detect exogenously expressed β-catenin 
using GFP antibody. D) SW480 cells pretreated with DMSO or 50 µM tolfenamic 
acid for 2 hours at 90% confluent and then co-treat with 10µg/ml CHX for indicated 






3.4 Tolfenamic acid-induced crosstalk between TGF-β/Smad and Wnt/β-catenin 
signaling 
 
There are growing evidences that transforming growth factor-β (TGF-β) /Smad 
and Wnt/β-catenin signaling cross-talk to each other (85, 86). In TGF-β signaling, 
Smad2 and Smad3 are major mediators(81).  Therefore, we hypothesized that Smad2 
and Smad3 are involved in tolfenamic acid-induced β-catenin degradation. 
Expression level of Smad2/Smad3 decreased in dose dependent manner with 
tolfenamic acid treatment in SW480 cells (Figure 3.4A). LoVo cells showed the same 
pattern as well (Figure 3.4B).  
Since TGF-β and Wnt are major activator of β-catenin-mediated oncogenic 
signaling pathway, we tested if tolfenamic acid influences TGF-β or Wnt-stimulated 
stability of β-catenin protein. The SW480 cells were co-treated with tolfenamic acid 
and TGF-β or Wnt3A for 24 hours. As shown in Figure 3.4C, tolfenamic acid did not 








Figure 3.4. Tolfenamic acid decreases expression of Smad2 and Smad3 via TGFβ 
and Wnt3 independent pathway A) SW480 cells were treated with indicated 
concentrations of tolfenamic acid for 24 hours. Cells were harvested with RIPA 
buffer and subjected to western blot assay using Smad2/Smad3 antibody and actin. B) 
LoVo cells were treated with indicated concentrations of tolfenamic acid for 24 
hours. Cells were harvested with RIPA buffer and subjected to western blot assay 
using Smad2, Smad3 and actin. C) SW480 cells were co-treated with 50µM 
tolfenamic acid and DMSO (control) or TGF β1 (2.5ng/ml) or WNT3 (150ng/ml) as 
labeled for 24 hours. Lysates were harvested and western blot was performed to 






3.5 Tolfenamic acid suppressed Smad2-stimulated transcriptional activity of β-
catenin 
 
Since Smad2 and Smad3 are downregulated by tolfenamic acid treatment, we 
hypothesized that Smad2 and Smad3 may be involved in tolfenamic acid-induced β-
catenin degradation.  Smad2 and Smad3 were overexpressed in the presence of 
SB216763 (selective inhibitor of GSK-3β) to block β-catenin degradation and then 
transcriptional activity of β-catenin were measured using TOP/FOP Flash lucierase 
system. Overexpression of Smad2 dramatically increased transcriptional activity of β-
catenin whereas Smad3 minimally affected β-catenin activity. Tolfenamic acid 
decreased Smad2-stimulated transcriptional activity of β-catenin. (Figure. 3.5). These 
data indicated that Smad2, but not Smad3, mediates tolfenamic acid-induced 







Figure 3.5. Tolfenamic acid suppressed Smad2-stimulated transcriptional 
activity of β-catenin A) SW480 cells were transfected with empty vector, Smad2 or 
Smad3 expression vector and then treated with tolfenamic acid for 24 hours. Cells 
were harvested with lysis buffer and luciferase activity was measured using a dual 





3.6 Tolfenamic acid reduced expression of β-catenin target genes. 
 
VEGF and cyclin D1 are downstream transcriptional activation oncogenic targets 
of β-catenin (63, 73-75). We observed whether tolfenamic acid could alter expression 
of VEGF and cyclin D1. Our result showed the expression level of VEGF and cyclin 







Figure 3.6. Tolfenamic acid reduced expression of β-catenin target genes. SW480 
were treated with tolfenamic acid as labeled for 24 hours. Lysates were harvested and 
western blot was performed to analyze the VEGF and cyclin D1 expression level. 







Chapter 4: Discussion, Conclusion and Future Perspective 
 
4.1 Discussion 
NSAIDs are used traditionally to treat pain, fever and inflammation. Tolfenamic 
acid is the one used to treat acute migraine in the UK. Like many other NSAIDs that 
exhibited anti-cancer activities, tolfenamic acid has been reported to inhibit the 
proliferation of lung, esophageal, breast, prostate, ovary and pancreatic cancer cell 
and tumor growth in vivo (43-49). Recently we found that tolfenamic acid suppressed 
formation of tumor in Apc
Min+/
 mice (55) and proposed several molecular 
mechanisms of anti-tumorigenic activity by tolfenamic acid. They include activation 
of tumor suppressive EGR-1, NAG-1 and ATF3 (52, 53). Other groups also indicated 
that anti-cancer activities of tolfenamic acid may involve in degradation of specificity 
protein (Sp) and suppression of TGF-β (98, 99).  
Aberrant Wnt/β-catenin regulation pathway is a major mechanism of colon 
tumorigenesis (20-22). In most colon cancer tissues, the β-catenin/TCF4-mediated 
oncogenic activity is constitutively active due to defective APC or β-catenin genes. 
Thus they could be a promising therapeutic target for colon cancer. Since Apc 
mutation is found in 90% of colon cancer patients and leads to constitutive activation 
of β-catenin signaling, we hypothesized that anticancer activities of tolfenamic acid 
might be associated with suppression of β-catenin pathway. Six different NSAIDs 
(sulindac sulfide, tolfenamic acid, aspirin, diclofenac, SC-560, celecoxib) and three 
dietary compounds (epigallocatechin-3-gallate, resveratrol and genistein) were 
screened based on suppression of β-catenin expression in SW480 cells. The result 




gallate treatment apparently decreased β-catenin expression. Sulindac sulfide is a 
metabolite of sulindac and effectively suppresses colon cancer as an inhibitor of 
COX-1 and COX-2 whereas it results in severe side effect including gastrointestinal 
ulceration and bleeding (100). Celecoxib (selective inhibitor of COX2) has been 
accepted as effective NSAIDs to inhibit inflammation but it also is associated with 
increased risk of cardiovascular side effects (10). However, it is generally accepted 
that tolfenamic acid show a little side effect compared to other NSAIDs (50). 
Epigallocatechin-3-gallate, resveratrol and genistein are very strong dietary 
antioxidants and their anticancer activities were already widely studied. Therefore, 
current study focused on tolfenamic acid as a potential effective anti-cancer drug and 
reliable anti-cancer mechanisms.  
Tolfenamic acid suppressed β-catenin expression in SW480, HCT116 and LoVo 
cells. Since both SW480 and LoVo cells are APC mutant cells whereas HCT116 is 
wild type Apc gene (61), effects of tolfenamic acid on down-regulation of β-catenin is 
likely go through Apc-independent pathways. In later studies, we chose SW480 cells 
as our model cells. Our data indicated the β-catenin mRNA level in SW480 cell was 
not changed with tolfenamic acid treatment, indicating that tolfenamic acid-
stimulated β-catenin downregulation is not at transcriptional level. We further showed 
tolfenamic acid induced β-catenin down-regulation was blocked by the treatment of 
MG-132. Moreover, exogenously GFP–tagged β-catenin was also decreased by 
tolfenamic acid. (Figure 3.3) Results strongly support that tolfenamic acid induces β-
catenin degradation through activating ubiquitin-proteasome system. However, 




Recent studies showed transforming growth factor-β (TGF-β) /Smad and Wnt/β-
catenin signaling cross-talk to each other (85, 86). In TGF-β signaling, Smad2 and 
Smad3 are major mediators (81).  In our study, we found that Smad2 and Smad3 are 
downregulated by tolfenamic acid treatment. Therefore, we purposed that Smad2 and 
Smad3 are involved in tolfenamic acid-induced β-catenin degradation. We found that 
tolfenamic acid suppressed Smad2-stimulated transcriptional activity of β-catenin 
(Fig. 3.5). Moreover, according to Dr. Ha’s data in our lab, overexpression of Smad2, 
but not Smad3, blocked tolfenamic acid-stimulated downregulation of β-catenin, 
which suggest that Smad2 might specifically regulate β-catenin in SW480 cells (data 
now shown). Taken together, Smad2 is upstream stimulator of β-catenin and 
tolfenamic acid suppresses expression of both Smad2 and β-catenin in human colon 
cancer cells.             
Furthermore, Cyclin D1 and VEGF are downstream targets of β-catenin (63, 73-
75). Cyclin D1 involved in G1 to S transition and activates cell cycles (73). VEGF is 
a key player in the process of angiogenesis. Tolfenamic acid decreased cyclin D1 and 
VEGF expression in dose dependent manner. Data were implied that decreasing of 
cyclin D1 and VEGF under tolfenamic acid treatment could be a consequence of 







Tolfenamic acid downregulated β-catenin through activating ubiquitination and 
subsequent proteasomal degradation of β-catenin. Decreased β-catenin activity led to 
a decreased expression of target gene such as VEGF and cyclin D1. Smad2 mediated 
tolfenamic acid-induced suppression of β-catenin transcriptional activity. All taken 
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